Even so, many are sticking with the stock. UBS analysts this week slashed their price target on the stock to 540 Danish kroner from 730 kroner as they cut survodutide peak sales by nearly 80%. "The tolerability data looks highly disappointing and will likely significantly limit its usage," they wrote in a research note. Shares of Danish biotech Zealand Pharma recently plunged after detailed data on its weight loss drug survodutide showed far higher patient dropout rates than leading treatments, prompting an ...